denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: by educational grants from AbbVie Inc.; Adaptive Biotechnologies Corporation; and Amgen, Inc.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Leukemia, ALL, Biological, antibodies, therapy sequence, Diseases, CLL, Therapies, CAR-Ts, Combinations, DLBCL, B-Cell Lymphoma, Technology and Procedures, immunotherapy, Lymphoid Malignancies, genetic profiling, flow cytometry, TKI, molecular testing, serologic tests
Hematology Disease Topics & Pathways:
Leukemia, ALL, Biological, antibodies, therapy sequence, Diseases, CLL, Therapies, CAR-Ts, Combinations, DLBCL, B-Cell Lymphoma, Technology and Procedures, immunotherapy, Lymphoid Malignancies, genetic profiling, flow cytometry, TKI, molecular testing, serologic tests
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Nitin Jain, MD, Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center
Disclosures:
Jain: Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; Pfizer: Research Funding; ADC Therapeutics: Research Funding; Incyte: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Cellectis: Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Precision Bioscienes: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Fate Therapeutics: Research Funding; Aprea Therapeutics: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees.
Speakers:
Mark Roschewski, MD, National Cancer Institute
,
Lori Muffly, MD, MS, Assistant Professor of Medicine, Stanford University School of Medicine
and
Nina Shah, MD, Associate Professor of Medicine, University of California San Francisco
Disclosures:
Muffly: Adaptive: Research Funding; Servier: Research Funding; Amgen: Consultancy. Shah: BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar: Research Funding; GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm: Consultancy.
The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. The live activity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data for MRD monitoring and their implications for clinical practice.
- The activity is designed to highlight and test participants on the most clinically relevant data in the use of MRD monitoring in hematologic malignancies, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
- The faculty panel will convene in Medical Crossfire panel discussions to share their own practice preferences (“How I treat”), perspectives on the clinical trial data and share clinical pearls from their own practices.
- To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.
See more of: Satellite Symposia